Palazidou 03

Dr Eleni Palazidou MD, PhD, MRCP, FRCPSYCH

1. Fawcett J, Barkin RL. J Clin Psychiatry . 1997; 58(Suppl 6): 32 – 39. 2. O'Reardon JP, Amsterdam JD. Psychiatr Ann 1998; 28: 633 – 640. Approximately 2/3 of patients treated for depression will fail to achieve remission (HAM-D ≤ 7) 2

1. Paykel ES, et al. Psychol Med 1995; 25: 1171 – 1180. Patients were interviewed at 3-monthly intervals according to the Clinical Interview for Depression and HAM-D 17 Rating Scale Depressed patients with unresolved symptoms are 3 times more likely to relapse 1

Kupfer DJ. J Clin Psychiatry 1991; 52 (5, Suppl): 28–34.

1. Acute Treatment
First 6-12 weeks of treatment - aims at remission (control of symptoms).
Inadequate response is associated with poor prognosis.
2. Continuation Treatment
6 months after full symptom control - to maintain remission status and relapse prevention.
3. Maintenance Treatment
Aims at prevention of recurrence of a further episode of depression.
Indicated when higher risk of these recurrence.
“ maintenance dose”

Treatment aims Complete symptom resolution Return to premorbid functioning (psychosocial, occupational) The maintenance of normality The prevention of recurrence

Limbic System Prefrontal Cortex Locus Coeruleus (NA source) Raphe Nuclei (5-HT source) Amygdala Hippocampus Cooper JR, et al. The Biochemical Basis of Neuropharmacology . 8th ed. New York: Oxford University Press; 2003. Descending 5-HT pathways Descending NA pathways

Normal situation Depression

Monoamine oxidase inhibitors
-non-selective, non-reversible (MAOIs)
-selective, reversible (RIMAs)
Monoamine re-uptake inhibitors
-non-selective NA & 5-HT (TCAs)
-selective NA & 5-HT (SNRIs)
-selective 5-HT (SSRIs)
-selective NA (NARIs)
Receptor selective antagonists
-alpha2 receptor antagonists – mianserin, mirtazapine
-5-HT2 receptor antagonists - trazodone

ACUTE MECHANISM OF ACTION UNDESIRABLE PHARMACOLOGICAL ACTIONS TCAs Anticholinergic; antihistaminic; alpha1 adrenoceptor blockade; direct membrane stabilisation SSRIs Citalopram(Cipromil), Fluoxetine (Prozac), Fluvoxamine(Faverin), Paroxetine(Seroxat), Sertraline (Lustral) 5-HT re uptake inhibition MAOIs Phenelzine(Nardil), Isocarboxazid(Marplan) Tranylcypromine(Parnate) Inhibition of MAO-A and MAO-B isoenzymes Interaction with tyramine and sympathomimetic drugs; Irreversible and non-selective inhibition of MAO isoenzymes RIMAs Moclobemide(Manerix) Reversible Inhibition of MAO-A SNRIs Venlafaxine(Efexor) Duloxetine(Cymbalta) 5-HT and NA re uptake inhibition Reboxetine(Edronax) NA re uptake inhibition Mirtazapine(Zispin) Alpha2 adrenoceptor blockade 5-HT2 receptor blockade

Normal situation Depression

Side effects ↑ Weight, sexual dysfunction, dry mouth, headache Safety in overdose Lethal (hypertensive crisis, stroke,MI) Sympathomimetics ¢ Tyramine foodstuffs ¢ Carbamazepine ¢ Hypertensive crisis β -blockers ↑ hypotension,bradycardia Oral hypoglycaemics ↑ hypoglycaemic effect SSRIs ¢ Nefazodone Serotonin Syndrome Bupropion ¢ Hypertensive crisis, seizures Clomipramine ¢

SIDE EFFECT PROFILE OF TRICYCLIC ANTIDEPRESSANTS Anticholinergic Dry mouth, Blurred vision Urinary hesitancy (urinary retention) Constipation Memory impairment Aggravation of narrow angle glaucoma Antihistaminic Sedation Weight gain Alpha1 adrenoceptor antagonism Orthostatic hypotension Cardiac effects Cardiovascular effects Sinus tachycardia Arrhythmias Conduction delay Sudden death Other side effects Sexual dysfunction Impaired cognitive and psychomotor skills Convulsions

SIDE EFFECT PROFILE OF SSRIs Nausea/vomiting* Abdominal pain Dry mouth Constipation/diarrhoea Headache* Asthenia Dizziness Insomnia/somnolence Sweating* Anorexia Weight loss Nervousness/agitation Tremor Convulsions Dystonic reactions Sexual dysfunction* (reduced libido, anorgasmia)

Serotonin Syndrome – Suggested Diagnostic Criteria
Coincident with the addition of or increase in a known serotonergic agent to
an established medication regimen,
at least three of the following clinical features are present:
mental status changes (confusion, hypomania)
agitation
myoclonus
hyperreflexia
diaphoresis
shivering
tremor
diarrhoea
incoordination
fever
Other aetiologies (e.g. infectious, metabolic, substance abuse or withdrawal)
have been ruled out.
A neuroleptic had not been started or increased in dosage prior to
the onset of the signs and symptoms listed above.

DISCONTINUATION SYNDROME
Dizziness *
Electric shock sensations *
Anxiety/agitation ٭
Insomnia
Flu-like symptoms
Diarrhoea/abdominal spasms
Paraesthesia *
Mood swings
Nausea
Low mood

Pharmacokinetic – cytochrome p450
Pharmacodynamic – MAOIs + SSRIs (serotonin syndrome)

CYP2 D6 polymorphism- autosomal recessive trait (slow or ultra-rapid metabolisers)

Tricyclic antidepressants
(Lofepramine)
Venlafaxine
MAOIs

Antidepressant drugs:
- Induction of mania/mixed states
- Cycle acceleration (rapid cycling)
- Uncertainty about duration of Rx

Choice of medication
Severity of illness
Clinical presentation
Suicidal risk
Previous response to treatment
The likely tolerability of potential side effects
The likely benefit of potential side effects such as sedation
The likely drawbacks of potential side effects such as sedation (i.e. working with machinery, driving etc)
Pregnancy or breastfeeding
Concomitant treatment of physical illness or other psychiatric disorders with the potential for pharmacokinetic/pharmacodynamic interactions.
The presence of relevant physical (for example cardiovascular) disease

Therapeutic alliance
Adequate information about the nature of their illness and the need for treatment.
A positive message about the treatability
Explain that antidepressants are not addictive, do not alter one’s personality nor affect their intelligence .
It may take about 2 -4 weeks before s/he their symptoms start showing significant improvement
T hey may experience some side effects
A ntidepressant could be changed if they are unable to tolerate the original drug prescribed.
Regular reviews of the patient’s mood state and suicidal risk offers further reassurance and support, helps ensure compliance and allows prompt intervention in the case of any serious worsening of the condition.

1960s-70s
First generation – “classical”
Phenothiazines - chlorpromazine
Butyrophenones - haloperidol
Thioxanthines - flupenthixol
From 1980s
Second generation – “atypicals”
Clozapine, olanzapine, quetiapine,
Sulpiride, amisulpride
Risperidone, paliperidone
Aripiprazole

Extrapyramidal
Parkinsonism
Dystonia
Akathisia
Tardive dyskinesia
Hyperprolactinaemia
Amenorrhoea
Low fertility
Sexual dysfunction
Cardiovascular – QT interval
Haematological
Weight gain
Lower seizure threshold
Drug interactions

Effective – when 60% D2 receptor occupancy EPS - when 80% D2 receptor occupancy (shown on PET scanning ) EPS Prevalence Rx parkinsonism 30% anticholinergic drugs amantadine dystonia 21%(young males) anticholinergic drugs akathisia 25% - 75% propranolol tardive dyskinesia 10-20% (>1year Rx) * neuroleptic malignant syndrome Males>females bromocriptine dantrolene diazepam

Schizophrenia Bipolar disorder Obesity 45-55% 26% Smoking 50-80% 55% Diabetes mellitus 10-14% 10% Hypertension >18% 15%

Reasons for intolerance (total 15%)
weight gain/metabolic – 4%
EPS – 4%
Sedation – 2%
Other – 5%
Efficacy on +ve and -ve symptoms
no difference between 1 st and 2 nd generation

Electrolyte imbalance ( ↓ K, ↓ Mg)
Underlying cardiac abnormalities
Hypothyroidism
Familial QT prolongation Σ
Drugs known to prolong QT

Higher risk of QTc prolongation and Torsades de Pointes – iv administration or high doses
Recent recommendation an ECG to be performed prior to Rx

Great variation in pharmacological profile!
In general they have decreased likelihood of extrapyramidal effects or hyperprolactinaemia
BUT
Weight gain
Diabetes
Metabolic syndrome

First generation Second generation Weight gain Hyperglycaemia, diabetes Insulin resistance Cardiovascular dis Dyslipidaemia Less EPS Less QT prolongation Less hyperprolactinaemia Neurological side effects EPS Tardive dyskinesia Hyperprolactinaemia

Antipsychotic drugs
Schizophrenia, other psychoses and any psychotic symptoms
sometimes useful as sedatives
Antidepressants
Depression
Anxiety
Obsessive compulsive disorder

Drug treatment needs to be tailored to the individual
The aim is to achieve full symptom control
Return to pre morbid functioning
Minimize side effects, ensure safety
Monitor progress over time as mental illnesses are long term relapsing conditions
Always check suicide risk

Palazidou 03

by henkpar

Accessibility

Categories

Upload Details

Usage Rights

Statistics

Palazidou 03 Presentation Transcript

Palazidou 03

by henkpar

Accessibility

Categories

Upload Details

Usage Rights

Statistics

Palazidou 03 Presentation Transcript

Let LinkedIn power your SlideShare experience

Let LinkedIn power your SlideShare experience

Customize SlideShare content based on your interests

Keep up to date when your LinkedIn contacts post on SlideShare